Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus

Chinese Medical Journal

Volumn 123, Issue 24, 2010, Pages 3640-3643

  Yang, Zhong Hua ^a   Peng, Xiao Dong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Diabetic cardiomyopathy; Type 2 diabetes mellitus; Valsartan

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; GLUCOSE; HYDROXYPROLINE; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DRUG EFFECT; HEART INDEX; HEART INJURY; HEART PROTECTION; HEART WEIGHT; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN CONTENT; PROTEIN LOCALIZATION; RAT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; APOPTOSIS; COLLAGEN TYPE I; COLLAGEN TYPE III; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; HYDROXYPROLINE; INSULIN RESISTANCE; MALE; MYOCARDIUM; RATS; RATS, WISTAR; TETRAZOLES; VALINE;

EID: 78650587497     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.24.024     Document Type: Article

References (23)

1. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
2. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Eng J Med 2001; 345: 861-869.
3. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al; Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbersartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
4. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
5. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-473.
6. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977-1982.
7. Frossard M, Joukhadar C, Steffen G, Schmid R, Eichler H G, Müller M, et al. Paracrine effects of angiotensin-converting-enzyme and angiotensin-II-receptor-inhibition on transcapillary glucose transport in humans. Life Sci 2000; 66: 147-154.
8. Muller M, Fasching P, Schmid R, Burgdorff T, Waldhäusl W, Eichler HG. Inhibition of paracrine angiotensin-converting enzyme in vivo: effects on interstitial glucose and lactate concentrations in human skeletal muscle. Eur J Clin Invest 1997; 27: 825-830.
9. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener E P, et al. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-139.
10. Codinach Huix P, Freixa Pamias R. Diabetic cardiomyopathy: concept, heart function and pathogenesis. An Med Interna 2002; 19: 313-320.
11. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25: 543-567.
12. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
13. Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy. JAMA 1974; 229: 1749-1754.
14. Francis GS. Diabetic cardiomyopathy: fact or fiction? Heart 2001; 85: 247-248.
15. Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005; 16: 120-126.
16. Chang-Quan H, Bi-Rong D, Qian X, Ping H, Qun-Fang D, Zhen-Chan L, et al. Renal injury, abnormal vitamin D metabolism and bone homeostasis in aged rats with insulin resistance or type 2 diabetes mellitus. J Investig Med 2008; 56: 872-877.
17. Chang-Quan H, Bi-Rong D, Ping H, Zhen-Chan L, Xiao-Dong P. Insulin resistance, renal injury, renal 1-alpha hydroxylase, and bone homeostasis in aged obese rats. Arch Med Res 2008; 39: 380-387.
18. Blaedel WJ, Uhl JM. Nature of materials in serum that interfere in the glucose oxidase-peroxidase-0-dianisidine method for glucose, and their mode of action. Clin Chem 1975; 21: 119-124.
19. Straczkowski M, Stepień A, Kowalska I, Kinalska I. Comparison of simple indices of insulin sensitivity using the euglycemic hyperinsulinemic clamp technique. Med Sci Monit 2004; 10: CR480-CR484.
20. Woessner Jr JE. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961; 93: 440-447.
21. Konduracka E, Gackowski A, Rostoff P, Galicka-Latala D, Frasik W, Piwowarska W. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 2007; 28: 2465-2471.
22. Ding A, Brian R. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006; 291: 1489-1506.
23. Feuvray D. Diabetic cardiomyopathy. Arch Mal Coeur Vaiss 2004; 97: 261-265.